Buteyko breathing for asthma inhaler down, lungs unchanged

One camp calls it a cure; the other calls it pseudoscience. Both are reading the same five trials - and both get the finding wrong: under medical supervision, alongside standard medication, reliever and steroid use reliably drops, while lung function itself doesn't move at all ^[1]11Cooper 2003. That split isn't a compromise between the two camps. It's what happened, checked five separate times, in four countries.

A real Buteyko course is a multi-week system, not the one exercise you already know

Most people meet Buteyko through one trick: pinch your nose, hold your breath, and a stuffy nose clears in a minute or two - an exercise we've covered on its own, and genuinely promising as one piece of the wider system ^[2]22Dallimore & Eccles 1977. The full method is much bigger. A real course, per Buteyko Clinic International's own curriculum and the trial protocols below, runs roughly five days of intensive instruction, then home practice twice daily for weeks to months ^[1]11Cooper 2003 ^[3]33Cowie 2008. It bundles nasal breathing at all times (including nightly mouth-taping in some variants), a daily practice of consciously slower, smaller breaths meant to induce mild air hunger, the Control Pause breath-hold test, structured timed breath-hold reps, and lifestyle rules against sighing, yawning, and slumped posture. It's a season-long training program, not an afternoon's trick.

Buteyko's physiology checks out; the disease theory built on it doesn't

Two pieces of the physiology behind Buteyko aren't in dispute. Rising carbon dioxide really does help release oxygen from blood into tissue - the Bohr effect, textbook respiratory physiology since 1904 ^[4]44StatPearls, oxygen transport. And a drop in blood CO2 really does narrow blood vessels, measurably, in the brain: PET scans put it at roughly −3.5% cerebral blood flow per mmHg of CO2 change ^[5]55Ito 2003. Buteyko built something far larger on those two real mechanisms: that most people chronically, invisibly overbreathe, and that this hidden hypocapnia is the root cause of a long disease list - asthma, hypertension, angina, and, in his own claims, dozens more ^[6]66Wikipedia, Konstantin Buteyko.

That larger claim has been tested directly, and it failed. Hornsveld and colleagues ran a double-blind, placebo-controlled trial on 115 patients suspected of chronic hyperventilation syndrome: a real hyperventilation-provocation test reproduced their symptoms - but so did an isocapnic placebo version, where CO2 was held artificially normal throughout ^[7]77Hornsveld 1996. If symptoms appear just as reliably when CO2 never drops, CO2 loss isn't what's causing them; separate monitoring found most real-life "attacks" weren't accompanied by any CO2 drop at all ^[7]77Hornsveld 1996. The same authors later called chronic hyperventilation syndrome "an elegant but scientifically untenable concept" ^[8]88Hornsveld & Garssen 1997. A separate critique makes the same point differently: Buteyko's theory predicts a near-universal lab signature across the roughly 150 conditions he claimed to treat, and it isn't routinely seen in practice ^[9]99Science-Based Medicine, Buteyko critique. The physics holds. The leap to a disease list does not.

The Control Pause was never validated, and the one direct test found it backwards

The Control Pause is Buteyko's signature measurement: breathe out normally, pinch your nose, and time the hold to the first definite urge to breathe - not your maximum. Clinics score it (under 10 seconds is "poor," 40-plus is "good health") and argue a longer hold means less chronic overbreathing, per Buteyko's own formula linking hold time to resting CO2 ^[10]1010Buteyko Clinic, breathing test ^[11]1111Courtney & Cohen 2008. That formula has been tested once, directly, against real capnography in 83 adults - and the correlation ran backwards: longer holds predicted lower resting CO2, not higher (r = −0.241, p < 0.05) ^[11]1111Courtney & Cohen 2008. Its sibling test, BOLT, fares no better: a 2024 study found it has never been scientifically validated and showed no significant link to fitness measures in trained athletes ^[12]1212BOLT validation study, 2024. The number isn't meaningless - it climbs with practice, which is what a trainable breath-hold does - but that makes it a practice marker, not a validated health index. Treat it as a practice marker, never a diagnosis.

Two different Buteyko verdicts: your reliever use drops, your lung function doesn't

Line the trials up and one pattern holds across five independently-run studies in four countries: under medical supervision, alongside standard medication, people practicing Buteyko-style breathing reliably use less reliever medication and fewer inhaled steroids, and report feeling better, than people in the comparison group ^[13]1313Bowler 1998 ^[1]11Cooper 2003 ^[3]33Cowie 2008 ^[14]1414Prem 2013 ^[15]1515McHugh 2003. In the best-controlled of the five, Buteyko beat a placebo breathing device on both symptom score (a 3-point drop on the symptom scale vs 0 for placebo, p = 0.003) and bronchodilator use (down roughly 2 puffs a day, p = 0.005) ^[1]11Cooper 2003.

Ask the same five trials about lung function, and the pattern reverses. Not one found a change in FEV1, airway responsiveness, or exacerbation rate ^[13]1313Bowler 1998 ^[1]11Cooper 2003 ^[15]1515McHugh 2003. Cooper's three-arm trial - roughly 30 people per arm, a genuine placebo-device comparator, the strongest single test of this exact question - came back a clean null on FEV1, PD20, and exacerbations ^[1]11Cooper 2003.

A Cochrane review of 22 breathing-exercise trials broadly agrees on quality of life - but read it carefully rather than quoting it as "Cochrane says Buteyko works": only 2 of the 22 trials were Buteyko, certainty ratings run very low to moderate, and its FEV1 finding is driven mostly by the yoga-arm studies in the pool ^[16]1616Santino 2020, Cochrane review. The five named trials above are the more honest, Buteyko-specific evidence - real, but narrower than one Cochrane citation implies.

The rest of Buteyko's disease list, named one by one

Beyond asthma, Buteyko clinics advertise relief for sleep apnoea, snoring, sinusitis, chronic bronchitis, COPD, allergies, panic attacks, and insomnia ^[17]1717Buteyko Clinic, benefits page. Name each claim individually and the evidence thins fast.

• Sleep apnoea: zero direct trials. A 2021 review co-authored by McKeown himself states plainly that "no clinical trials specifically testing [breathing re-education] protocols for OSAHS phenotypes are presented" in the literature ^[18]1818McKeown 2021. Mouth-breathing worsening OSAHS severity is a real, established fact - but logic plus zero trials is curious, not evidence of benefit.
• Anxiety: one small trial surfaces in a 2024 Australian government evidence review, but the primary source couldn't be independently verified ^[19]1919Australian Government evidence review, Appendix J. Broader literature links dysfunctional breathing to anxiety generally, a plausible mechanism - but one unverifiable trial plus a general link is curious, not a Buteyko-specific finding.
• Rhinitis in asthmatics: the only evidence is a letter, not a trial - 26 people, no confirmed comparator, self-reported ^[20]2020Adelola 2013. A different claim from the isolated nose-unblocking maneuver, which carries its own separate, better-supported grade - one uncontrolled letter is curious, not a fair test either way.
• Hypertension, diabetes, cancer: no independent trial evidence at all. These trace to Buteyko's own unreplicated 1959 Soviet-era case series ^[6]66Wikipedia, Konstantin Buteyko, not to any Western RCT.
• Long COVID: no Buteyko-named trial exists, in either direction.

One narrower claim inside the method has been tested and failed cleanly: nightly mouth-taping. A crossover of 51 people found no difference in morning peak flow or symptom scores between taped and untaped nights ^[21]2121Cooper 2009, mouth-taping trial.

Who's selling Buteyko, and the certification economy behind it

Patrick McKeown is the method's dominant modern popularizer: he discovered Buteyko breathing at 26 after a lifetime of asthma medication, trained with Buteyko's own organization in Russia, and founded Buteyko Clinic International in 2002 ^[22]2222Oxygen Advantage, McKeown bio. His own training is in arts and business at Trinity College Dublin, not medicine - Buteyko was a physician; the clinics carrying his name today aren't staffed by physicians by default ^[22]2222Oxygen Advantage, McKeown bio. In 2015 he added a second brand, Oxygen Advantage, aimed at athletes, built on the same breath-hold toolkit. Over 23 years he reports training 3,000-plus healthcare professionals across 50-plus countries through paid, multi-day certification courses ^[23]2323Buteyko Clinic, certification pages.

That's the real cross-pillar tension here: the organisations producing most of the West's popularising Buteyko content also sell paid certifications and clinic sessions - and it's precisely the broadest, least-supported version of the claim, the full disease list above, that they're most commercially invested in. One independent review put it bluntly: "the Buteyko Center and BIBH are willing to start doling out details in exchange for the digits on your credit card" ^[9]99Science-Based Medicine, Buteyko critique. McKeown himself also helped design or deliver the intervention arm in more than one trial cited above - common in complementary medicine, and reason to hold the marketing and the evidence at arm's length from each other.

Independent voices land close to this article. Science-Based Medicine separates the "conventional aspects of Buteyko" - which "appear to improve quality of life and reduce the need for medication" - from "foundational Buteyko principles" that have been disproven ^[9]99Science-Based Medicine, Buteyko critique. Skeptical Inquirer calls it "a wonderful example of how genuine benefits...can be undermined by a dogmatic obsession with quack medicine" ^[24]2424Tiller, Skeptical Inquirer 2021. Australia's own government review found "no clear evidence of effectiveness" ^[25]2525Wikipedia, Buteyko method - a mixed verdict from yet another angle.

What is NOT proven

Put plainly, in one place: no Buteyko-specific trial has found a change in lung function, ever, in the studies that measured it ^[1]11Cooper 2003 ^[13]1313Bowler 1998 ^[15]1515McHugh 2003. The disease list beyond asthma - sleep apnoea, anxiety, hypertension, diabetes, cancer, long COVID - has essentially no independent trial evidence in either direction; it traces to marketing and to Buteyko's own unreplicated case series, not controlled trials ^[6]66Wikipedia, Konstantin Buteyko. Mouth-taping, isolated and fairly tested, does not improve asthma control ^[21]2121Cooper 2009, mouth-taping trial. The Control Pause has never been validated as a general health index, and the one study that tested Buteyko's own formula found the relationship ran the wrong way ^[11]1111Courtney & Cohen 2008. And whether the medication-use finding is a genuine physiological effect, or partly a supervised self-management effect - a coach checking in, the confidence to try cutting back - can't be cleanly separated from what the trials measured ^[1]11Cooper 2003. None of that makes the medication-use finding untrue. It marks the honest edge of what five real trials actually showed.

Brizzy doesn't teach Buteyko itself - the full system needs real in-person coaching to do safely at the depth clinics practice it. What we offer is the closest related shape: gentle, slow-paced breathing, related to Buteyko's core reduced-volume practice, not a substitute for it.

Buteyko breathing is never a substitute for your prescribed asthma medication

Myths and facts

FAQ

Does Buteyko breathing actually work for asthma?

For symptom control, yes - five independent trials across four countries found people needed less reliever and steroid medication, alongside standard care. For lung function, no: the best-controlled trial found no change in FEV1 or exacerbations. Both are true, not competing opinions.

Can Buteyko breathing replace my asthma inhaler?

No. None of the trials tested or endorsed stopping preventer medication, and no one should reduce or stop prescribed asthma treatment without a doctor's involvement. What was tested is reducing reliever use under supervision, alongside continued care.

How do I measure my Control Pause?

Breathe normally, exhale gently, pinch your nose, and time the hold to the first definite urge to breathe - not your maximum. Clinics score the result, but the one study that tested whether the score predicts what it claims found the opposite, so treat your number as a curiosity, not a diagnosis.

Does Buteyko help with sleep apnoea, anxiety, or other conditions?

The evidence is thin to nonexistent outside asthma. Sleep apnoea has zero direct trials; anxiety has one unverifiable one. Hypertension, long COVID, and the rest of the claimed disease list trace to decades-old case reports, not modern controlled trials.

Is Buteyko breathing pseudoscience?

Not entirely - that's the mirror-image overreach. Five independent trials show a real, replicated effect on medication use and symptom scores; a Cochrane review agrees on quality of life, though only 2 of its 22 pooled trials were Buteyko and certainty runs very-low to moderate. What fails is the theory Buteyko proposed to explain why, and the long disease list built on it.

For professionals

For a clinician or researcher who wants the trial architecture, not just the headline: the five core asthma RCTs vary in comparator design, which matters for how much weight each carries. Cooper 2003 is the strongest single test - three arms, a genuine sham-device placebo, ~30 completers per arm - and the source of both the cleanest positive (symptom score: Buteyko −3 vs placebo 0, p = 0.003; bronchodilator use down ~2 puffs/day, p = 0.005) and cleanest negative (FEV1, PD20, exacerbations) findings in the set ^[1]11Cooper 2003. Cowie 2008 is the largest (65/64), but its comparator was an active physiotherapist-led breathing programme, not a passive control - its asthma-control-rate result is a superiority test between two breathing interventions, not a bare efficacy test, though its ICS-reduction advantage (p = 0.02) still holds against that active comparator ^[3]33Cowie 2008. Bowler 1998 and McHugh 2003 sit below the N = 25/arm replication bar individually but replicate the same direction ^[13]1313Bowler 1998 ^[15]1515McHugh 2003. Santino 2020's pooled FEV1%pred estimate (+6.88%) carries very-low certainty and is driven mostly by the yoga-arm studies in its 22-trial pool, not the 2 Buteyko trials within it ^[16]1616Santino 2020, Cochrane review.